Linus Health’s Post

Linus Health researchers have developed a rapid, AI-assisted neuropsychological protocol that can be remotely administered and scored in just 10 minutes, specifically designed to assess neurocognitive functions associated with emerging neurodegenerative diseases. Tested on patients from ambulatory care and memory clinics, this protocol combines traditional core measures with detailed error analysis and process variables. The results indicate that this digital protocol can efficiently and accurately detect early signs of neurodegenerative illnesses, offering a reliable alternative to standard paper-and-pencil tests.   Learn more in Frontiers in Psychology: https://lnkd.in/gCXMK77m I #AlzheimersDisease #AlzheimersResearch #BrainHealth #CognitiveDecline #MildCognitiveImpairment Ali Jannati, MD, PhD Sean Tobyne David Bates Alvaro Pascual-Leone

When The Washington Post contributor Steven Petrow was in his mid-40s, a stressful period led him to fear he was losing his memory, as he struggled to recall words and phrases. He even suspected he might have a brain tumor. After a cognitive assessment, he was relieved to learn he had an anxiety disorder, not a cognitive deficit. Petrow emphasizes the importance of regular cognitive testing, particularly for those over 65, to monitor changes and intervene early if necessary. While Medicare now covers cognitive assessments during annual wellness visits, some primary care doctors are hesitant to administer them due to uncertainty about which tests to use, how to interpret the results, and what to do with abnormal findings. With the urgency for innovation in cognitive care growing, digital cognitive assessments are emerging as tools for earlier detection and intervention in brain health. https://lnkd.in/g5s-Q_jd I #AlzheimersDisease #BrainHealth #EarlyDetection #Dementia

New research from Linus Health confirms that early detection of Alzheimer's disease and cognitive impairment is critical to improving the healthcare trajectories of aging adults, enabling early intervention and potential prevention of decline. Published in Alzheimer's Association®’s Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) Journal, researchers evaluated  multimodal feature sets for assessing memory impairment. The research revealed that incorporating graphomotor, memory, and speech and voice features provided stronger classification performance. This study adds to the understanding of the multimodal profile of individuals with cognitive impairment, indicating that their speech tends to be slower, with noticeable effects on the duration, frequency, and percentage of pauses compared to normal, healthy speech. https://lnkd.in/enp4Fcrv I #AlzheimersDisease #AlzheimersResearch #BrainHealth #CognitiveDecline #MildCognitiveImpairment Ali Jannati, MD, PhD David Bates Sean Tobyne Alvaro Pascual-Leone

We recently shared the news that Linus Health acquired Together Senior Health (Together), a brain health company delivering evidence-based solutions for individuals with cognitive decline, Alzheimer's disease and related dementias.   Worldwide dementia cases are projected to surge from 55 million in 2020 to over 139 million by 2050. Meanwhile, the demand for neurologists is expected to exceed supply by 20% as early as next year. Combining Together Senior Health’s capabilities and our innovative solutions, Linus Health is poised to remotely detect early signs of cognitive impairment and initiate a lifestyle-based intervention plan, delivering greater benefits to patients and their care partners. Learn more in Healthcare IT Today: https://lnkd.in/ghe4ksnM I #AlzheimersDisease #AlzheimersPrevention #DementiaPrevention #BrainHealth

The electronic Person-Specific Outcome Measure (ePSOM) development program is a scalable, systematic, and automated process that captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias. At the 2024 Alzheimer's Association® International Conference, Linus Health unveiled groundbreaking ePSOM survey results assessing what matters to people aged 50 and older about their brain health in the U.S. Led by Linus Health Personalized Medicine Lead Dr. Stina Saunders, the study highlighted significant differences in the pattern of responses between subgroups: younger/older; male/female; higher/lower education; and U.K./U.S. populations but not between those with and without a diagnosis. In an interview with NeurologyLive's Marco Meglio, Dr. Saunders shared the innovative edge of ePSOM, its game-changing clinical impact, and exciting plans for broader validation and expansion. https://lnkd.in/eCqS2UPP I #AlzheimersDisease #AlzheimersPrevention #DementiaPrevention #BrainHealth #AAIC2024

The brain is constantly changing, unlike a static computer. Some argue that if the brain, a biological machine, can be conscious, then a sufficiently advanced artificial machine could be, too. However, this overlooks the fundamental difference between living organisms and computers. Marc Wittmann Ph.D. explores in Psychology Today how living beings, including their brains, are dynamic, continually exchanging energy and matter with their environment, leading to constant physical and psychological changes. Wittmann cites Linus Health Cofounder and CMO Alvaro Pascual-Leone: “The brain is never the same from one moment to the next throughout life. Never ever.” This dynamic nature, intrinsic to life and consciousness, cannot be replicated by AI, which lacks the continuous flux essential for conscious experience. Thus, AI, despite its complexity, will never truly possess consciousness. https://lnkd.in/gHDwnChA I #AlzheimersDisease #ArtificialIntelligence #BrainHealth #AlzheimersResearch

Could a diabetes drug offer new hope for protecting the brains of patients living with early Alzheimer’s disease? A recent Phase 2 study led by Imperial College London investigated the GLP-1 drug liraglutide, used for obesity and diabetes, in early Alzheimer's patients. Although it did not meet its primary endpoint related to brain sugar use, the study found that liraglutide significantly reduced brain shrinkage in memory and learning regions by nearly 50% and slightly slowed cognitive decline. The results, presented at the Alzheimer's Association® International Conference, suggest that GLP-1 drugs might have potential benefits for neurodegenerative diseases by reducing inflammation and addressing brain insulin resistance, though these theories still need further human trial validation. Linus Health is excited that Novo Nordisk's evoke trails are on track to be completed by the end of 2025, which will provide Phase 3 trial results for GLP-1 drugs. Read more in STAT: https://lnkd.in/g94uqERC I #AlzheimersDisease #BrainHealth #AlzheimersResearch #DementiaResearch #GLP1 #Liraglutide

The Linus Health Team had an incredible week at Alzheimer's Association®’s International Conference (AAIC) learning about and sharing emerging research and meeting with clients, colleagues and media. From engaging presentations to inspiring discussions, here's a quick recap of the highlights that made this event memorable: ▶ Sharing more than a dozen AAIC sessions and posters tied to Linus Health research that covered topics ranging from using artificial intelligence (AI) in digital cognitive assessment tools to the integration of a digital cognitive assessment tool in a primary care setting ▶ Hearing from Stina Saunders, PhD, Personalized Medicine Lead, Linus Health, on: “The electronic Person-Specific Outcome Measure (ePSOM) in the US population: What matters to individuals the most about their brain health” ▶ Sitting in on a (packed-house) presentation from Ali Jannati, MD, PhD, Director of Cognitive Science, Linus Health, on “Validation of Clinical Decision Support Recommendations of a Digital Cognitive Assessment by Expert Cognitive Neurologists” ▶ Showcasing our digital cognitive assessment platform, which is revolutionizing research and clinical practice by streamlining workflows and care pathways. Didn’t get a chance to connect with us at AAIC? Contact us to learn more about how Linus Health can help your organization support cognitive health research: https://lnkd.in/dV7KeJXj I #AAIC2024 #AAIC24 #AlzheimersAwareness #BrainHealth #AlzheimersResearch #DementiaResearch

“The brain is never the same from one moment to the next throughout life. Never ever,” -Linus Health Co-founder and Chief Medical Officer Alvaro Pascual-Leone MD. In a conversation with Massachusetts Institute of Technology Press Reader’s Adolfo Plasencia Diago, Dr. Pascual-Leone explores topics such as the brain's capacity for change, how time perception is influenced by brain plasticity, and the potential risks of technologies that can read and manipulate brain activity. https://lnkd.in/g6aBXyRZ  I #BrainHealth #Dementia #AlzheimersDisease #AlzheimersResearch https://lnkd.in/g6aBXyRZ I #BrainHealth #Dementia #AlzheimersDisease #AlzheimersResearch

It’s been a productive few days at Alzheimer's Association® International Conference (AAIC)! We’ve enjoyed meeting with colleagues, customers, and members of the media, sharing firsthand how the Linus Health platform is helping organizations support cognitive health research. If you haven’t already, swing by Booth #830 to see our platform in action. Some highlights include: ▶ Presentation by Stina Saunders, PhD, Personalized Medicine Lead, Linus Health, on “The electronic Person-Specific Outcome Measure (ePSOM) in the US population: What matters to individuals the most about their brain health.” Dr. Saunders also spoke with NeurologyLive’s Marco Meglio about how treatments in Alzheimer's Disease and Related Dementias (ADRD) should be developed with a person-centered approach and explored the differences in treatment priorities across the UK and US populations and across sociodemographic groups within these populations. ▶ Presentation by Ali Jannati, MD, PhD, Director of Cognitive Science, Linus Health, on “Validation of Clinical Decision Support Recommendations of a Digital Cognitive Assessment by Expert Cognitive Neurologists.” ▶ Showcasing how our digital cognitive assessment platform empowers researchers and clinicians by streamlining workflows and care pathways through combined objective analysis of cognitive performance and qualitative metrics, all augmented with clinical expertise and AI. ▶ Sharing our more than a dozen AAIC sessions and posters, covering research topics ranging from using artificial intelligence (AI) in digital cognitive assessment tools to the integration of a digital cognitive assessment tool in a primary care setting. Click here to learn about the latest study findings from Linus Health: https://lnkd.in/e2X4WjZc I #AAIC2024 #AAIC24 #AlzheimersAwareness #BrainHealth #AlzheimersResearch #DementiaResearch